Known targets — ChEMBL curated mechanism
GRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5
The experimentally established mechanism targets of Tezampanel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 known ✓ | P42261 | 3/20 | 0.65 |
| ▸ | GRIA2 known ✓ | P42262 | 3/20 | 0.65 |
| ▸ | GRIA3 known ✓ | P42263 | 3/20 | 0.65 |
| ▸ | GRIA4 known ✓ | P48058 | 3/20 | 0.65 |
| ▸ | GRIK1 known ✓ | P39086 | 1/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.65 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.65 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.65 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.65 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezampanel Anhydrous SCHEMBL29227429 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL13320011 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3688366 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3227089 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3688367 | 1.00 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL5508469 | 0.99 | GRIA1 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL14179393 | 0.90 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL2783303 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8867563 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL20553364 | 0.88 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | claimed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | claimed |
| CN-117836284-A | Methods of treating nerve agent-induced seizures | 普罗尼拉斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117715638-A | Methods of treating or preventing conditions associated with opioid withdrawal or opioid relapse | 普罗尼拉斯公司 | 2024-03-15 | — | — | CN | disclosed |
| US-8603980-B2 | Glutamate receptor antagonists and methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2164487-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164489-A2 | COMBINATION OF AMPA RECEPTOR ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2150248-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | The Johns Hopkins University (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009011411-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011412-A2 | COMBINATION OF AMPA RECEPTOR ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| US-7439270-B2 | Drugs for spinal anesthesia | UNIVERISTY OF IOWA RESEARCH FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439270-B2 | Drugs for spinal anesthesia | UNIVERISTY OF IOWA RESEARCH FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008088820-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2005049041-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20030073683-A1 | Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury | BELAYEV LUDMILA (US) | 2003-04-17 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | GRIA1 115/4885GRIA2 201/4885GRIA3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.